+2.12%
Today
Loading 1D prices…
Company profile
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Scottsdale, AZ, United States
Employees
58
Fiscal year end
1231
CIK
1867066
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ANTXAN2 Therapeutics Inc. Common Stock | $204.2M | $0.00 | — | -$1.16 | -4.92% | Buy |
| TNXPTonix Pharmaceuticals Holding Corp. Common Stock | $203.6M | $13.1M | -946.22% | -$14.57 | -3.34% | Buy |
| KRROKorro Bio Inc. Common Stock | $203.4M | $6.4M | -1834.48% | -$12.48 | +5.74% | Buy |
| PEPGPepGen Inc. Common Stock | $206.1M | $0.00 | — | -$2.12 | -1.16% | Buy |
| MSLESatellos Bioscience Inc. Common Stock | $206.9M | $0.00 | — | -$1.70 | +1.49% | Buy |